Sorrento Therapeutics, Inc. Form SC 13D/A May 06, 2016 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D (Rule 13d-101)

(Amendment No. 2)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

Sorrento Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

83587F202 (CUSIP Number)

Leonard A. Potter

President and Managing Member

Wildcat Capital Management, LLC

888 Seventh Avenue

New York, NY 10106

(212) 468-5100

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 5, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

*Note.* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 14 Pages)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

\_\_\_\_\_

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

# **CUSIP No. 83587F202 13D Page 2 of 14 Pages**

1	NAMES OF REPORTING PERSONS		
	Wildcat Capit CHECK THE APPROPRIA' A MEMBER GROUP	ГЕ В	_
2	(see instructio	ns)	
	(a)		
3	(b) SEC USE ON SOURCE OF instructions)		DS (see
4	mor actions)		
	OO (See Item CHECK IF DISCLOSUR	•	,
5	LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF		
6	ORGANIZATION		
O	D 1		
	Delaware	7	SOLE VOTING POWER
			-0-
			SHARED
NUMBER OF			VOTING
SHARES		0	POWER
DENIE	EICIALLV	8	2.400.036 (\$22
BENEFICIALLY OWNED BY			2,499,936 (See Items 3, 4 and
EACH REPORTING			5)
LACII KLFUKTINU		9	SOLE
PERSON WITH		_	DISPOSITIVE

**POWER** 

-0-10 SHARED DISPOSITIVE POWER

2,499,936 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

2,499,936 (See Items 3, 4 and

5)

CHECK BOX IF

THE

AGGREGATE AMOUNT IN

12 ROW (11)

EXCLUDES CERTAIN

SHARES (see instructions)

PERCENT OF CLASS REPRESENTED BY

13 AMOUNT IN ROW 11

6.5% (See Item 5)\*
TYPE OF REPORTING

PERSON 14

OO

The calculation assumes that there are a total of 38,365,767 shares of Common Stock (as defined herein) outstanding \*as of March 10, 2016, as set forth in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (the "SEC") on March 15, 2016.

# **CUSIP No. 83587F202 13D Page 3 of 14 Pages**

1	NAMES OF F PERSONS	REPC	PRTING
	Wildcat – Liqu CHECK THE APPROPRIA' A MEMBER O GROUP	ГЕ В	OX IF
2	(see instructio	ns)	
	(a)		
3	(b) SEC USE ON SOURCE OF instructions)		DS (see
4			
5	WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF		
3			
6	ORGANIZAT		
	Delaware	7	SOLE VOTING POWER
NUMBER OF SHARES		8	-0- SHARED VOTING POWER
OWNE	FICIALLY ED BY REPORTING	U	184,000 (See Items 3, 4 and 5)
	ON WITH	9	SOLE DISPOSITIVE POWER

-0-10 SHARED DISPOSITIVE POWER

184,000 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

184,000 (See Items 3, 4 and

5)

CHECK BOX IF

THE

AGGREGATE AMOUNT IN

12 ROW (11)

EXCLUDES CERTAIN SHARES (see

instructions)

PERCENT OF CLASS REPRESENTED BY

13 AMOUNT IN ROW 11

0.5% (See Item 5)\*
TYPE OF REPORTING

PERSON 14

OO

# **CUSIP No. 83587F202 13DPage 4 of 14 Pages**

1	NAMES OF R PERSONS	ES OF REPORTING ONS			
1	Infinity Q Cap	ital N	Ianagement,		
	CHECK THE APPROPRIAT A MEMBER O GROUP				
2	(see instruction	ns)			
	(a)				
3	(b) SEC USE ON SOURCE OF		DS (see		
4	instructions)				
	OO (See Item	3)			
	CHECK IF				
	DISCLOSURI	E OF			
5	LEGAL PROCEEDING	CC IC	•		
3	REQUIRED	03 13	•		
	PURSUANT T	го гт	TEM		
	2(d) or 2(e)	1011	LIVI		
	CITIZENSHII	P OR	PLACE OF		
6	ORGANIZAT		1 2.102 01		
	Delaware				
			SOLE		
		_	VOTING		
		7	POWER		
			-0-		
MI IMPED OF			SHARED		
NUMBER OF SHARES			VOTING POWER		
SHAKES		8	TOWER		
BENEF	TCIALLY	J	123,597 (See		
OWNED BY			Items 3, 4 and		
EACH REPORTING			5)		

```
Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A
```

#### PERSON WITH

**SOLE** 

**DISPOSITIVE** 

9 POWER

-0-

10 SHARED DISPOSITIVE

**POWER** 

123,597 (See

Items 3, 4 and

5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

123,597 (See Items 3, 4 and

5)

CHECK BOX IF

THE

AGGREGATE AMOUNT IN

12 ROW (11)

**EXCLUDES** 

**CERTAIN** 

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

0.3% (See Item 5)\*

TYPE OF REPORTING

PERSON

00

# **CUSIP No. 83587F202 13DPage 5 of 14 Pages**

1	NAMES OF F PERSONS  Infinity Q Ma LLC CHECK THE APPROPRIA' A MEMBER OF	nager TE B	ment Equity,
2	(see instructio	ns)	
	(a)		
3	(b) SEC USE ON		DS (222
4	SOURCE OF instructions)	FUN	D3 (see
5	OO (See Item CHECK IF DISCLOSUR LEGAL PROCEEDIN REQUIRED PURSUANT 2(d) or 2(e) CITIZENSHII ORGANIZAT	E OF GS IS TO IT	ГЕМ
	Delaware		SOLE
		7	VOTING POWER
NUMBER OF SHARES		8	-0- SHARED VOTING POWER 123,597 (See
BENEFICIALLY OWNED BY EACH REPORTING			Items 3, 4 and 5)

```
Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A
```

#### PERSON WITH

SOLE

**DISPOSITIVE** 

9 POWER

-0-

10 SHARED

DISPOSITIVE

**POWER** 

123,597 (See

Items 3, 4 and

5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

123,597 (See Items 3, 4 and

5)

**CHECK BOX IF** 

THE

AGGREGATE

AMOUNT IN

12 ROW (11)

EXCLUDES

CERTAIN

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

0.3% (See Item 5)\*

TYPE OF REPORTING

PERSON

OO

### **CUSIP No. 83587F202 13DPage 6 of 14 Pages**

```
NAMES OF REPORTING
      PERSONS
1
      Infinity Q Diversified Alpha Fund
      CHECK THE
      APPROPRIATE BOX IF
      A MEMBER OF A
      GROUP
2
      (see instructions)
      (a)
      (b)
      SEC USE ONLY
3
      SOURCE OF FUNDS (see
      instructions)
4
      WC (See Item 3)
      CHECK IF
      DISCLOSURE OF
      LEGAL
5
      PROCEEDINGS IS
      REOUIRED
      PURSUANT TO ITEM
      2(d) or 2(e)
      CITIZENSHIP OR PLACE OF
      ORGANIZATION
6
      Delaware
                      SOLE
                      VOTING
                  7
                     POWER
                      -0-
                      SHARED
NUMBER OF
                      VOTING
SHARES
                      POWER
                  8
BENEFICIALLY
                      123,597 (See
                     Items 3, 4 and
OWNED BY
EACH REPORTING
                      5)
                  9
```

```
Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A
```

PERSON WITH

SOLE

DISPOSITIVE

**POWER** 

-0-

10 SHARED

DISPOSITIVE

**POWER** 

123,597 (See

Items 3, 4 and

5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

123,597 (See Items 3, 4 and

5)

**CHECK BOX IF** 

THE

AGGREGATE

AMOUNT IN

12 ROW (11)

**EXCLUDES** 

**CERTAIN** 

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

0.3% (See Item 5)\*

TYPE OF REPORTING

PERSON

OO

# **CUSIP No. 83587F202 13DPage 7 of 14 Pages**

1	NAMES OF REPORTING PERSONS			
1	Bonderman Fa Partnership CHECK THE			
	APPROPRIATA A MEMBER O GROUP			
2	(see instruction	ns)		
	(a)			
3	(b) SEC USE ON SOURCE OF		DS (see	
4	instructions)			
5	WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION			
	Texas	7	SOLE VOTING POWER	
			-0- SHARED	
NUMBER OF SHARES		0	VOTING POWER	
BENEFICIALLY OWNED BY EACH REPORTING		8	2,623,533 (See Items 3, 4 and 5)	
PERSON WITH		9	SOLE DISPOSITIVE	

```
Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A
```

**POWER** 

-0-

10 SHARED DISPOSITIVE POWER

2,623,533 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

2,623,533 (See Items 3, 4 and

5)

CHECK BOX IF

THE

**AGGREGATE** 

AMOUNT IN

12 ROW (11)

**EXCLUDES** 

**CERTAIN** 

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

6.8% (See Item 5)\*

TYPE OF REPORTING

PERSON 14

PN

# **CUSIP No. 83587F202 13D Page 8 of 14 Pages**

1	NAMES OF REPORTING PERSONS		
	Leonard A. Po CHECK THE APPROPRIAT A MEMBER ( GROUP	E BO	OX IF
2	(see instruction	ns)	
	(a)		
3	(b) SEC USE ON SOURCE OF I		OS (see
4	,		
	OO (See Item : CHECK IF DISCLOSURE LEGAL		
5	PROCEEDING REQUIRED PURSUANT T 2(d) or 2(e) CITIZENSHIF ORGANIZAT	TO IT	EM
6	ORGANIZAT	IOIV	
	United States	7	SOLE VOTING POWER
NUMB! SHARE			-0- SHARED VOTING POWER
SHAKE	.S	8	FOWER
BENEFICIALLY OWNED BY		-	2,623,533 (See Items 3, 4 and
EACH REPORTING		0	5)
9 PERSON WITH		9	SOLE DISPOSITIVE

**POWER** 

-0-

10 SHARED

DISPOSITIVE

**POWER** 

2,623,533 (See

Items 3, 4 and

5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

2,623,533 (See Items 3, 4 and

5)

CHECK BOX IF

THE

**AGGREGATE** 

**AMOUNT IN** 

12 ROW (11)

**EXCLUDES** 

CERTAIN

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

6.8% (See Item 5)\*

TYPE OF REPORTING

PERSON 14

IN

### **CUSIP No. 83587F202 13DPage 9 of 14 Pages**

```
NAMES OF REPORTING
      PERSONS
1
      James Velissaris
      CHECK THE
      APPROPRIATE BOX IF
      A MEMBER OF A
      GROUP
2
      (see instructions)
      (a)
      (b)
      SEC USE ONLY
3
      SOURCE OF FUNDS (see
      instructions)
4
      OO (See Item 3)
      CHECK IF
      DISCLOSURE OF
      LEGAL
5
      PROCEEDINGS IS
      REQUIRED
      PURSUANT TO ITEM
      2(d) or 2(e)
      CITIZENSHIP OR PLACE OF
      ORGANIZATION
6
      United States
                     SOLE
                      VOTING
                  7
                     POWER
                      -0-
                      SHARED
                      VOTING
NUMBER OF
SHARES
                     POWER
                  8
BENEFICIALLY
                      123,597 (See
                     Items 3, 4 and
OWNED BY
EACH REPORTING
                      5)
```

9

```
Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A
```

PERSON WITH

SOLE

DISPOSITIVE

**POWER** 

-0-

10 SHARED

DISPOSITIVE

**POWER** 

123,597 (See

Items 3, 4 and

5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

123,597 (See Items 3, 4 and

5)

**CHECK BOX IF** 

THE

AGGREGATE AMOUNT IN

ROW (11)

12

**EXCLUDES** 

**CERTAIN** 

SHARES (see

instructions)

PERCENT OF CLASS

REPRESENTED BY

13 AMOUNT IN ROW 11

0.3% (See Item 5)\*

TYPE OF REPORTING

PERSON

IN

This Amendment No. 2 (the <u>"Amendment"</u>) amends and supplements the Schedule 13D filed on April 18, 2016, as amended and supplemented by Amendment No. 1 filed on April 26, 2016 (as so amended, the <u>"Original Schedule 13D"</u> and, as further amended and supplemented by this Amendment, the <u>"Schedule 13D"</u>) by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

#### Item 4. Purpose of Transaction

This Amendment amends and restates the fourth paragraph of Item 4 of the Original Schedule 13D in its entirety as set forth below:

"Accordingly, on April 25, 2016, WLA filed a verified complaint for the inspection of books and records (the "Complaint") in the Court of Chancery of the State of Delaware seeking an order compelling the Issuer to provide WLA certain books and records of the Issuer for inspection and copying pursuant to Section 220 of the Delaware General Corporation Law. A copy of the Complaint is attached as Exhibit 3.

On May 5, 2016, WLA and BFLP submitted a letter (the "May 5 Letter") to the Issuer's board of directors (the "Board") reiterating certain concerns regarding the Transactions and additionally setting forth their belief that (i) the Issuer's Chief Executive Officer ("CEO"), Dr. Henry Ji, has consistently acted in a manner that is not in the best interests of the Issuer's shareholders and has destroyed significant shareholder value and (ii) the Board has failed to act in the best interests of the Issuer's shareholders and has breached its fiduciary duties owed to such shareholders. Accordingly, WLA and BLFP set forth certain demands in the May 5 Letter, including that the Board: (i) immediately terminate Dr. Ji as the CEO; (ii) immediately terminate the Transactions that have not already closed to avoid further dilution to the existing shareholders; (iii) appoint three directors to be nominated by WLA and BFLP to lead a special committee of the Board (the "Special Committee") to undertake the actions necessary to preserve and maximize shareholder value; (iv) authorize the Special Committee to seek and appoint an interim CEO and, if necessary, a permanent replacement for Dr. Ji with more commercial and executive experience; (v) authorize the Special Committee to engage an investment banker to initiate a sale process for the entire company; (vi) in the event that there are no buyers for the entire company, authorize the Special Committee to sell selected non-strategic assets of the Issuer, including its minority investments in private companies, and unwind its minority positions in joint ventures so that it can focus on, maintain control of, and finance the development of the Issuer's remaining assets; and (vii) in the event that neither the Issuer nor selected assets can be sold, management and the Special Committee should develop a well-defined and financed business plan that maximizes the value of the Issuer's existing assets and further, the Issuer should immediately stop any further financial engineering efforts and under no circumstances should the Issuer acquire any additional assets for development. The May 5 Letter also provided that if the Board refuses to meet WLA's and BFLP's demands, the Board should immediately resign and allow another slate of directors to take the actions that are required to protect and maximize shareholder value. Further, to address certain concerns regarding option and warrant grants, WLA and BFLA intend to pursue their available remedies including, among other things, legal action on the Issuer's behalf. A copy of the May 5 Letter is attached as Exhibit 4.

Wildcat has raised, or may further raise, its concerns regarding the Transactions, management of the Issuer, the Board and related matters with management or directors of the Issuer, other shareholders and regulators."

#### Item 7. Material to Be Filed as Exhibits

This Amendment amends and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

- 1. Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.
- 2. Demand for Inspection of Books and Records, dated April 11, 2016.

Page 10 of 14

3. Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016.

4. Letter to the Board of Directors of the Issuer, dated May 5, 2016.

Page 11 of 14

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 6, 2016

Wildcat Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter

Title: President

Wildcat - Liquid Alpha, LLC

By: /s/ Clive Bode
Name: Clive Bode
Title: President

Infinity Q Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u>
Name: Leonard A. Potter
Title: Chief Executive Officer

Infinity Q Management Equity, LLC

By: /s/ James Velissaris
Name: James Velissaris
Title: Sole Manager

Infinity Q Diversified Alpha Fund

By: Infinity Q Capital Management, LLC

By: /s/ Leonard A. Potter
Name: Leonard A. Potter
Title: Chief Executive Officer

Page 12 of 14

## Bonderman Family Limited Partnership

By: <u>/s/ Clive Bode</u>
Name: Clive Bode
Title: President

Leonard A. Potter

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter

James Velissaris

By: <u>/s/ James Velissaris</u> Name: James Velissaris

Page 13 of 14

#### **INDEX TO EXHIBITS**

- Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.\*
   Demand for Inspection of Books and Records, dated April 11, 2016.\*\*
   Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016.\*\*\*
  - 4. Letter to the Board of Directors of the Issuer, dated May 5, 2016.

Page 14 of 14

<sup>\*</sup>Incorporated herein by reference to the Agreement of Joint Filing by and among Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, dated as of April 18, 2016, which was previously filed with the SEC as Exhibit 1 to Schedule 13G filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

<sup>\*\*</sup>Incorporated herein by reference to Demand for Inspection of Books and Records, dated April 11, 2016, which was previously filed with the SEC as Exhibit 2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

<sup>\*\*\*</sup>Incorporated herein by reference to Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016, which was previously filed with the SEC as Exhibit 3 to Amendment No. 1 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 26, 2016.